DATE: Saturday, May 10, 2025
LOCATION: DoubleTree by Hilton, Downtown Toronto (108 Chestnut St, Toronto, ON M5G 1R3, Canada)

We are pleased to host the inaugural Canadian Hidradenitis Suppurativa Symposium (CHSS), a multidisciplinary event taking place on May 10, 2025, in Toronto, Ontario (Hilton DoubleTree, Chestnut Street).

This landmark symposium will bring together dermatologists, gastroenterologists, rheumatologists, surgeons, primary care providers, and allied health professionals to explore innovative strategies for managing Hidradenitis Suppurativa (HS). With a strong focus on advancing research, improving clinical care, and fostering multidisciplinary collaboration, CHSS provides a unique opportunity to support healthcare professionals and improve outcomes for patients affected by this challenging condition.

The meeting aims to:

• Share the latest research and clinical insights on HS.

• Explore current and emerging treatment options, including biologics and small molecules.

• Foster multidisciplinary collaboration to improve care for HS patients, particularly those with complex co-morbidities such as inflammatory bowel disease (IBD), psoriasis, and psoriatic arthritis (PsA).

• Discuss challenges in patient care, including early diagnosis, paradoxical reactions, and access to timely treatment.

• Highlight innovative approaches, including procedural interventions, surgical techniques, and emerging technologies.

Co-Chairs

David Croitoru, MD MSc FRCPC FAAD

Jessica Asgarpour, MD BSc FRCPC FAAD

Who Should Attend?

Dermatologists | Gastroenterologists | Rheumatologists | Surgeons | Primary Care Providers | Allied Health Professionals

Behavioral Management of HS

• Lifestyle factors influencing HS outcomes, including diet, smoking cessation, and mechanical triggers

Medical Management of HS

• Overview of topical therapies (washes, antibiotics, retinoids)

• Systemic treatments: antibiotics, immunosuppressives, and hormonal therapies

• Biologics and small molecules: current options, emerging therapies, and late-breaking data

• Managing comorbidities and addressing paradoxical reactions in HS care

Procedural Management of HS

• Advances in laser therapies (CO2 and hair removal)

• Use of botulinum toxin in HS treatment

Surgical Management of HS

• Including de-roofing, excision, and incision/drainage (I&D)

Clinical Scoring & Outcome Tools in HS

• Evaluation of existing tools, common pitfalls, and controversies in clinical practice

Wound Care & Pain Management in Active HS

• Approaches to topical, intralesional, and systemic analgesia

THANK YOU TO OUR SPONSORS

GOLD

SILVER

BRONZE

PLATINUM